To our ENCORE Community and Industry Partners,
ENCORE is taking the COVID-19 crisis seriously, in part by understanding that clinical trials will provide the only durable solution to this crisis and other afflictions facing our community and country.
All of our ENCORE sites are open for business for both patient and industry visits. We have added precautions to minimize the risk of virus transmission to patients and employees and to ensure that ongoing clinical trials are completed.
We have instituted more frequent and aggressive cleaning and infection control procedures. We also ask anyone with acute influenza-like symptoms or those who have been in close contact with individuals that have tested positive for COVID-19 to reschedule after following the federal guidelines for 14-day self-isolation. In taking sensible precautions, we hope our patients and industry partners will feel comfortable that our ongoing operations don’t put our community at risk…only benefit it.
We do understand some of our industry partners have implemented additional requirements for their staff and we are prepared to accommodate them remotely or virtually in order to keep projects moving forward.
Analysis of Clinicaltrials.gov shows there are nearly 80 clinical trials worldwide for investigational new treatments and vaccines in development. About 15 of those have been expanded to take place in the United States, of which, we aim to take part.
Michael Koren, MD, FACC, FAPCR, CPI Medical Director and Chief Executive Officer